-The Indian Express Responding to specific queries on the issue, Bhupendra Singh, NPPA chairman, told The Indian Express that “examination of hospital records is in process”. AFTER the National Pharmaceutical Pricing Authority (NPPA) in February ordered a cap on the prices of coronary stents and directed hospitals to issue separate bills specifying their cost, the drug pricing watchdog has started receiving consumer complaints against hospitals which are allegedly hiking the prices...
More »SEARCH RESULT
Total Matching Records found : 1081
Left-led Kerala govt will be first in country to provide insurance, free medical treatment for migrant workers -Rejimon K
-Firstpost.com Bhupesh Roy is from Assam but he is a long way from home. He has been working in the southern state of Kerala in the construction sector for the past four years and earns around Rs 500 a day, for an average of 20 days a month. “Two months ago, I fell sick. I had food poisoning and was admitted to hospital. I had fever too. For a week, I...
More »Stents can still make a killing -GS Mudur
-The Telegraph New Delhi: The government's price cap on coronary stents has not deterred the health-care industry from continuing to offer hospitals profit opportunities of tens of thousands of rupees on other kinds of stents, concerned doctors and health-care industry representatives said. The National Pharmaceutical Pricing Authority (NPPA), the government's price regulator, had on February 15 imposed a cap of about Rs 30,000 on coronary stents. But hospitals can continue to...
More »Generic medicines in a digital age -Dinesh S Thakur & Prashant Reddy T
-The Hindu We need a legal mechanism to ensure that all generics are of the same standard as the innovator product The Prime Minister’s recent announcement on making it mandatory for doctors to prescribe only the generic name, and not brand name of a drug, has led to a flutter. If enacted, the move will make it illegal for Indian doctors to write out a prescription for the trademark of the drug,...
More »Centre cracks whip, no stent can be withdrawn, for now -Sushmi Dey
-The Times of India NEW DELHI: The government has invoked special powers under the law to prohibit stent makers from withdrawing their products from the market for the next six months. Amid reports that several manufacturers, including Abbott and Medtronic, are seeking to withdraw premium, high-priced stents from the Indian market on account of the price cap imposed by National Pharmaceutical Pricing Authority (NPPA), the government has directed companies to maintain production,...
More »
